Telix and Regeneron target solid tumors in $2.1B radiopharma pact
The companies will co-develop and co-commercialize next-generation radiopharmaceutical therapies, with Telix receiving $40M upfront and eligibility for up to $2.1B in milestones.
Telix Pharmaceuticals and Regeneron have entered a strategic collaboration to develop and commercialize next-generation radiopharmaceutical therapies. The agreement covers 4 initial therapeutic programs.
Regeneron will use its antibody discovery and development platforms, including VelocImmune, across multiple solid-tumor targets. Telix will contribute radiopharmaceutical development, manufacturing, and supply capabilities.
Under the agreement, Telix will receive $40M upfront for access to its radiopharmaceutical manufacturing platform for the 4 initial programs. Regeneron has the option to expand the collaboration to 4 additional programs with further upfront payments.
The companies will use a 50/50 cost and profit-sharing model for global commercialization. Telix also retains the option, on a program-by-program basis, to co-fund commercialization and profit-share or receive milestone payments and royalties instead.
If Telix does not opt into cost and profit-sharing for a program, it may receive up to $535M in development and commercial milestones for that program, plus low double-digit royalties on net sales. Across the initial 4 programs, potential milestones total up to $2.1B.
The collaboration will also include radiodiagnostic development to support patient selection and treatment-response assessment. Telix said the approach is intended to pair therapeutic development with companion precision-medicine imaging.
Regeneron’s entry into targeted radiopharmaceuticals follows increased industry interest in pairing biologics-based tumor targeting with radioisotope delivery. The companies said the initial programs will focus on solid tumors, including lung cancer.
Companies:Regeneron, Telix Pharmaceuticals
Regeneron coverage
About the author
RadiologySignal.com writersEditorial Team
Radiology Signal Staff covers developments across medical imaging, radiology AI, imaging informatics, clinical research, and radiology business. The team monitors primary sources, peer-reviewed studies, company announcements, society updates, and healthcare industry news to deliver concise reporting for imaging professionals.
More from this section
Niowave breaks ground on $75M Ac-225 production facility
The Lansing, MI, site will house superconducting linear accelerators and radiochemistry systems to support scalable actinium-225 production, with completion expected in 2028.
GE HealthCare, UW Medicine launch imaging research collaboration
The collaboration will focus on CT and molecular imaging technologies for cardiology, oncology, and theranostics workflows at UW Medicine Radiology facilities in Seattle.
Radnostix reports 27% Q1 revenue decline
The radioisotope-focused company reported $2.38M in Q1 revenue, citing recall impacts, isotope shortages, and Cobalt-60 hot cell downtime.
Plus Therapeutics signs AI deal with Ephemeral
The companies will develop an AI platform to integrate therapeutic, diagnostic, and bioinformatics data across Plus Therapeutics’ CNS oncology programs.
Fujifilm launches balloon-less EBUS bronchoscope
The EB-710US Ultrasound Bronchoscope is designed for pulmonary procedures and will be demonstrated at the American Thoracic Society Conference.
ACIST wins FDA clearance for Pro Diagnostic System
The Bracco company received U.S. clearance and launched ACIST Pro, a variable-rate contrast management system for image-guided cardiovascular procedures.
Braid Health launches $199 radiology second-opinion service
Patients can upload MRI, CT, X-ray, or ultrasound files and receive a written second opinion from a board-certified U.S. radiologist.
QT Imaging prices $10M public offering
QT Imaging Holdings priced a $10M underwritten public offering of common stock and pre-funded warrants. The breast imaging technology company plans to use proceeds for working capital and general corporate purposes.
PSMA PET guidance anchors EDAP-Telix HIFU prostate work
EDAP TMS and Telix Pharmaceuticals signed a letter of intent to explore clinical research combining Focal One Robotic HIFU with Telix PSMA PET imaging agents in prostate cancer care.
UnitedHealthcare cites radiology costs in Maryland premium request
UnitedHealthcare is seeking an average 7.9% mid-year premium increase for some Maryland small-group plans. The insurer cited rising outpatient costs, including radiology, lab pathology, infusion, and radiation therapy.
Lumexa adds 4 imaging centers, including first UPMC JV site
Lumexa Imaging added 4 outpatient imaging centers across Pennsylvania, North Carolina, South Carolina, and Florida. The expansion includes acquired centers through joint ventures with UPMC and Advocate Health, plus 2 newly built locations.
PAI report finds 82% of U.S. physicians are now employed
A new PAI-Avalere report found that 82% of U.S. physicians are employed by hospitals, health systems, or corporate entities. Physician-owned settings now account for 18% of physicians and 36.1% of practices.